ArticleThe oncologist2026
Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe symptom burden associated with advanced pancreatic cancer, such as metastatic pancreatic adenocarcinoma (mPC), reduces patients' health-related quality of life (HRQoL). Recognizing the impact of disease- and treatment-related symptoms is essential in refining patient-reported outcomes (PROs) in clinical research, ensuring that PRO measures in clinical trials support US Food and Drug Administration label statements, and improving patient HRQoL. PATIENTS AND
methodsPatients with mPC and caregivers of patients with mPC were interviewed for this qualitative study. Insights from interviews were used to update a preliminary conceptual model derived from a targeted literature review. The primary objective was to obtain an in-depth understanding of patients' experience of living with mPC and the impact of mPC on patients' lives.
resultsAcross 19 interviews (n = 16 patients, n = 3 caregivers), the most frequently reported symptoms were tiredness (n = 19); fatigue, nausea, and weight loss (n = 18 each); and diarrhea and hair loss/thinning (n = 16 each); 17 participants reported mPC- and/or treatment-related pain. The most frequently reported impacts were anxiety (n = 17), reduced physical functioning (n = 16), and worry/fear of disease (n = 16). After identification of the most salient symptoms and impacts, two symptoms and four impacts were added to the preliminary conceptual model and 31 symptoms and 11 impacts were removed to generate the final conceptual model (40 symptoms and 26 impacts).
conclusionThis qualitative interview study uncovered previously unreported symptoms and impacts of mPC and supports the careful selection of appropriate PRO measures that more comprehensively reflect the experience of patients with mPC in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.